Celularity (CELU) Total Liabilities (2018 - 2025)
Celularity's (CELU) quarterly Total Liabilities came in at $145.4 million in Q4 2025, up 17.4% year-over-year from $123.8 million in Q4 2024, and up 8.23% quarter-over-quarter from $134.3 million in Q3 2025.
Analysis
Celularity (CELU) Total Liabilities (2018 - 2025) Analysis & Trends
Celularity (CELU) has reported Total Liabilities for 8 consecutive years, with $145.4 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Total Liabilities rose 17.4% year-over-year to $145.4 million in Q4 2025; TTM through Dec 2025 was $145.4 million, a 17.4% increase from a year earlier, with the FY2025 full-year figure at $145.4 million, up 17.4% from the prior year.
- Total Liabilities was $145.4 million for Q4 2025 at Celularity, up from $134.3 million in the prior quarter.
- Over five years, Total Liabilities peaked at $352.1 million in Q3 2021 and troughed at $39.8 million in Q1 2021.
- A 5-year average of $171.6 million and a median of $134.4 million in 2025 frame the typical range for Total Liabilities.
- Across the five-year window, Total Liabilities soared 3112.99% in 2021 and plunged 54.18% in 2023, its largest moves.
- Over 5 years, Total Liabilities stood at $314.7 million in 2021, then plunged by 35.76% to $202.2 million in 2022, then slumped by 49.09% to $102.9 million in 2023, then increased by 20.32% to $123.8 million in 2024, then increased by 17.4% to $145.4 million in 2025.
- The last three Total Liabilities figures came in at $145.4 million (Q4 2025), $134.3 million (Q3 2025), and $145.8 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 141.52 Mn |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | 904.22 Mn |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | 179.49 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | 521.30 Mn |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 661.05 Mn |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | 318.91 Mn |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 126.72 Mn |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 1.66 Bn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 132.83 Mn |
| 10 | Celularity | 36.35 Mn | 30.17 Mn | -3.27 Mn | 145.39 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 145.39 Mn |
| Sep 30, 2025 | 134.33 Mn |
| Jun 30, 2025 | 145.78 Mn |
| Mar 31, 2025 | 134.38 Mn |
| Dec 31, 2024 | 123.85 Mn |
| Sep 30, 2024 | 111.56 Mn |
| Jun 30, 2024 | 107.68 Mn |
| Mar 31, 2024 | 112.57 Mn |
| Dec 31, 2023 | 102.93 Mn |
| Sep 30, 2023 | 126.95 Mn |
| Jun 30, 2023 | 127.92 Mn |
| Mar 31, 2023 | 206.79 Mn |
| Dec 31, 2022 | 202.17 Mn |
| Sep 30, 2022 | 272.88 Mn |
| Jun 30, 2022 | 279.19 Mn |
| Mar 31, 2022 | 344.30 Mn |
| Dec 31, 2021 | 314.71 Mn |
| Sep 30, 2021 | 352.07 Mn |
| Jun 30, 2021 | 47.45 Mn |
| Mar 31, 2021 | 39.77 Mn |